Lakefront Biotherapeutics discloses six weeks of share buybacks through July 31
The company reported repurchasing nearly 588,000 shares for about €15.1 million since late June under a program announced June 9, 2026.
SEC filing (6)
Latest
Tuesday, August 4
BioCryst updates cost estimate for closing Alabama discovery facility
The company now pegs one-time severance costs at $6.2 to $7.5 million after saying in June it could not yet quantify the expense.
SEC filing
Lisata cuts 72% of workforce, terminates CMO amid Kuva Labs merger dispute
Lisata Therapeutics slashed staff and lost its R&D chief on August 3, 2026, while suing Kuva Labs over an alleged breach of their merger agreement.
SEC filing
BioNTech names Guido Oelkers CEO, trims 2026 revenue guidance in Q2 update
The company reported a wider net loss and cut its full-year revenue outlook to €1.6–1.9 billion while confirming Oelkers will succeed Ugur Sahin by February 2027.
SEC filing (2)
JNJ's Taubert to retire; Cavanaugh named EVP, Worldwide Chairman Innovative Medicine
Johnson & Johnson said Jennifer Taubert is stepping down after more than two decades at the company, with Tom Cavanaugh taking over effective September 1, 2026.
SEC filing
Rani Therapeutics adds Michelle Gilson to board, names her audit chair
The appointment took effect August 1, 2026, and Gilson brings prior CFO and equity research experience in biotech to the role.
SEC filing
Novo Nordisk registers Phase 3 cagrilintide trial; Penn semaglutide study posts results
Evolus expands Symatese pact to add Canada, Australia, New Zealand for Estyme
The amendment gives Evolus exclusive rights to sell the HA gel line in three more markets, with commercialization targeted for 2028.
SEC filing
Iovance registers two new trials: IOV-5001 solid tumor study and lifileucel sarcoma trial
Rhythm reports Q2 2026 IMCIVREE revenue of $71.3 million, strong HO launch uptake
More than 400 patient start forms were filed for IMCIVREE in acquired hypothalamic obesity as RM-718 posted early efficacy data in the same disease.
SEC filing
CervoMed's neflamapimod gets UK Innovation Passport for Lewy body dementia
The designation gives CervoMed early, coordinated access to UK regulatory, health system, and reimbursement bodies as it seeks a partner for a planned Phase 3 trial.
SEC filing
Lilly wins two label supplements: orforglipron tablet and teriparatide solution
Monday, August 3
Lantheus merger with Curium subsidiary confirmed at up to $114.50 per share
A Curium merger unit will merge into Lantheus, which survives as Curium's subsidiary, with holders getting $102.50 cash plus CVRs worth up to $12.00.
SEC filing
Supernus and Indivior agree to all-stock merger of equals
The companies will combine into Supernus, Inc., a CNS-focused biopharmaceutical company, with closing expected in the fourth quarter of 2026.
SEC filing
Indivior raises 2026 guidance on record SUBLOCADE revenue
The company reported second-quarter 2026 results on August 3 and lifted its full-year revenue and profitability targets while its planned merger with Supernus is expected to close in the fourth quarter.
SEC filing
Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meeting
The company reported a May 2026 Type C meeting confirmed its SOL-1 trial with confirmatory evidence is sufficient for a wet AMD submission, and posted $598.6 million in cash as of June 30, 2026.
SEC filing
Krystal Biotech posts second-quarter results, outlines multiple late-2026 pipeline readouts
The company reported VYJUVEK sales growth, described progress on European launches, and set timelines for several ophthalmology, respiratory, dermatology, and oncology programs.
SEC filing
Universiti Sains Malaysia updates registry record NCT07741812: not yet recruiting
Autolus enters $250 million notes facility with Perceptive Credit Holdings
Autolus drew a $75 million first tranche on July 30, 2026, with up to $175 million more available across three additional tranches tied to revenue milestones.
SEC filing
Autolus reports Q2 AUCATZYL revenue, raises 2026 guidance, secures $250M facility
The company posted preliminary Q2 net product revenue and lined up a five-year credit facility with Perceptive Advisors as it raised full-year sales guidance.
SEC filing
Vertex raises 2026 revenue guidance, sets povetacicept PDUFA date and Crinetics deal timing
Vertex lifted its full-year revenue outlook and disclosed a November 30 FDA decision date for povetacicept in IgA nephropathy while confirming plans to close its Crinetics acquisition in the third quarter.
SEC filing
Seaport Therapeutics reports Q2 2026 results, cites GlyphAgo Phase 1 win and IPO close
The company said cash of $427.3 million should fund operations into 2029 as it advances GlyphAllo and GlyphAgo through mid-stage trials.
SEC filing
Outlook Therapeutics posts Phase 3 results for ONS-5010 in wet AMD trial
Alzamend Neuro sells $7.5 million in preferred stock, flags board independence gap
The company closed the first tranche of a Series D preferred stock deal with an affiliate and told Nasdaq its board no longer has a majority of independent directors.
SEC filing
XORTX board sees departure and new appointment within days in July 2026
Chairman Anthony Giovinazzo left the board on July 31 while independent director Depesh Narotam joined effective July 27, 2026.
SEC filing (2)
Stoke Therapeutics files $200 million at-the-market stock offering
The August 3, 2026 prospectus supplement replaces a prior offering under which Stoke had already sold about 4.7 million shares for $146.4 million in net proceeds.
SEC filing
Keros reports second-quarter 2026 results as Phase 2 rinvatercept DMD trial gets underway
Keros initiated its Phase 2 trial of rinvatercept in Duchenne muscular dystrophy and still expects initial data in the first half of 2027, while cash fell to $257.6 million.
SEC filing
Moleculin prices $9.3M offering of stock and warrants at $0.75/share
Moleculin Biotech priced a public offering of common stock, pre-funded warrants, and common warrants, with share delivery expected around August 3, 2026.
SEC filing (2)
Cue Biopharma names James Ahlers as chief financial officer
The Boston biotech said Ahlers, a longtime life sciences finance executive, took the CFO role effective July 30, 2026, with a base salary of $450,000.
SEC filing
Twist Bioscience posts record quarterly revenue, raises full-year guidance
The company reported $118.4 million in fiscal third-quarter revenue and raised its fiscal 2026 revenue outlook to $456-$457 million.
SEC filing
Merck registers Phase 3 ovarian cancer trial, plus Phase 1 study of MK-1406 in healthy adults
Supernus and Indivior agree to merge as Supernus reports second-quarter growth
Supernus announced a definitive all-stock merger of equals with Indivior on the same day it posted 32% revenue growth and raised full-year guidance.
SEC filing
Indivior and Supernus agree to merge, forming Supernus, Inc.
Indivior will absorb Supernus in a stock-for-stock deal that renames the combined company and pays holders a $1 billion special dividend.
SEC filing
TG Therapeutics posts Q2 2026 results, raises BRIUMVI revenue guidance
The company raised its full-year 2026 revenue targets and reported positive Phase 3 data supporting a simplified BRIUMVI dosing regimen.
SEC filing
Eikon Therapeutics discloses two board resignations effective July 31, 2026
The company said neither departure stemmed from a disagreement over its operations, policies, or practices.
SEC filing
Crinetics reports Q2 2026 results alongside pending $10 billion Vertex acquisition
Crinetics disclosed the Vertex merger agreement, an FDA rare pediatric disease designation for atumelnant, and PALSONIFY sales growth in its second-quarter update.
SEC filing
BioLife shares employee video from Repligen CEO on pending merger
BioLife Solutions filed an 8-K on August 3, 2026 disclosing a video message from Repligen's CEO to BioLife employees about the companies' planned merger.
SEC filing
MD Anderson registers Phase 2 trial of Summit's ivonescimab in rare adrenal cancers
Lipocine appoints Michael Grissinger to board of directors
The biopharmaceutical company expanded its board to five members, adding a former Johnson & Johnson licensing and M&A executive effective August 3, 2026.
SEC filing
Obsidian Therapeutics completes merger with Galera, closes $350 million private placement
The combined company begins trading as OBX on Nasdaq August 4, 2026, with cash expected to fund operations into the second half of 2028.
SEC filing
ORIC Pharmaceuticals starts Phase 3 Himalayas-1 trial, adds Bayer supply deal
ORIC reported second quarter 2026 results with the Himalayas-1 prostate cancer trial underway, a darolutamide supply pact with Bayer, and cash guided into second half 2028.
SEC filing
Alkermes expands Blair Jackson's role to President and CEO, sets pay and board seat
The board added the President title, approved compensation and equity awards, and named Jackson a director, all effective August 1, 2026.
SEC filing
Ascentage Pharma names new Chief Business Officer and Chief Commercial Officer
The company appointed Dr. Faiçal Miyara as CBO and Jim Ziegler as CCO on August 2, 2026, dividing global deal-making from U.S. and ex-China commercial duties.
SEC filing
Moleculin Biotech closes $9.3 million public offering with Roth Capital as placement agent
The offering priced shares and warrants at $0.75 apiece, with proceeds earmarked for Annamycin development and working capital.
SEC filing
Nuvation Bio registers Phase 1 famotidine interaction study for taletrectinib
Stoke reports full EMPEROR enrollment, sets pre-NDA meeting and Q1 2027 filing start
Stoke Therapeutics said its Phase 3 EMPEROR trial in Dravet syndrome finished enrolling 162 patients, with a data readout expected in the third quarter of 2027 and a rolling NDA submission targeted to begin in early 2027
SEC filing
LifeVantage board approves new employee incentive plan, reserves 1.5 million shares
The plan, adopted without stockholder approval under Nasdaq inducement rules, is limited to new hires as an incentive for joining the company.
SEC filing
Design Therapeutics updates RESTORE-FA trial design, reports Q2 2026 results
The company is adjusting its Friedreich ataxia trial after early data and has begun dosing in a new myotonic dystrophy study, with $207.4 million in cash on hand.
SEC filing
CRISPR Therapeutics reports Q2 2026 results, expanded CASGEVY approval and new trial starts
FDA cleared CASGEVY for children as young as 2, and the company began Phase 1 trials for CTX340 and CTX460 while cash stood at $2,364.4 million.
SEC filing
Jazz Pharmaceuticals reports 2Q26 results, raises 2026 revenue guidance
Jazz reported record quarterly revenue of $1.2 billion and set up a possible near-term launch of Ziihera in a new gastric cancer indication.
SEC filing